{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:28:33Z","timestamp":1779917313239,"version":"3.53.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016040","name":"Takeda Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s41669-024-00523-5","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T12:02:03Z","timestamp":1728388923000},"page":"41-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study"],"prefix":"10.1007","volume":"9","author":[{"given":"Aren","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica Stivelman","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Ramos-Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"18","key":"523_CR1","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMra1102942","volume":"365","author":"S Danese","year":"2011","unstructured":"Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713\u201325. https:\/\/doi.org\/10.1056\/NEJMra1102942.","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"523_CR2","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/jcag\/gwy054","volume":"2","author":"GG Kaplan","year":"2019","unstructured":"Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, et al. The impact of inflammatory bowel disease in Canada 2018: epidemiology. J Can Assoc Gastroenterol. 2019;2(Suppl. 1):S6-16. https:\/\/doi.org\/10.1093\/jcag\/gwy054.","journal-title":"J Can Assoc Gastroenterol."},{"issue":"3","key":"523_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11894-023-00863-y","volume":"25","author":"J Claytor","year":"2023","unstructured":"Claytor J, Kumar P, Ananthakrishnan AN, Colombel JF, Agrawal M, Ungaro RC. Mild Crohn\u2019s disease: definition and management. Curr Gastroenterol Rep. 2023;25(3):45\u201351. https:\/\/doi.org\/10.1007\/s11894-023-00863-y.","journal-title":"Curr Gastroenterol Rep"},{"issue":"Suppl 1","key":"523_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000506364","volume":"101","author":"MC Sulz","year":"2020","unstructured":"Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, On behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment algorithms for Crohn\u2019s disease. Digestion. 2020;101(Suppl 1):43\u201357. https:\/\/doi.org\/10.1159\/000506364.","journal-title":"Digestion"},{"issue":"4","key":"523_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/1744666X.2023.2185605","volume":"19","author":"A Kohli","year":"2023","unstructured":"Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Rev Expert Rev Clin Immunol. 2023;19(4):431\u20138. https:\/\/doi.org\/10.1080\/1744666X.2023.2185605.","journal-title":"Rev Expert Rev Clin Immunol."},{"issue":"7","key":"523_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.2174\/13816128113199990416","volume":"20","author":"JK Ko","year":"2014","unstructured":"Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20(7):1082\u201396. https:\/\/doi.org\/10.2174\/13816128113199990416.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"523_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","volume":"5","author":"V Jairath","year":"2020","unstructured":"Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):2\u20133. https:\/\/doi.org\/10.1016\/S2468-1253(19)30358-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"523_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11894-019-0705-6","volume":"21","author":"JW Windsor","year":"2019","unstructured":"Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40.","journal-title":"Curr Gastroenterol Rep"},{"key":"523_CR9","doi-asserted-by":"publisher","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published erratum appears in Lancet. 2020 Oct;396(10256):e56]. Lancet. 2017;390(10114):2769\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0.","DOI":"10.1016\/S0140-6736(17)32448-0"},{"issue":"2","key":"523_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/MIB.0000000000000272","volume":"21","author":"G Huppertz-Hauss","year":"2015","unstructured":"Huppertz-Hauss G, H\u00f8ivik ML, Langholz E, Odes S, Sm\u00e5stuen M, Stockbrugger R, et al. Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015;21(2):337\u201344. https:\/\/doi.org\/10.1097\/MIB.0000000000000272.","journal-title":"Inflamm Bowel Dis"},{"issue":"9\u201310","key":"523_CR11","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1111\/jocn.16446","volume":"32","author":"P Thapwong","year":"2023","unstructured":"Thapwong P, Norton C, Rowland E, Farah N, Czuber-Dochan W. A systematic review of the impact of inflammatory bowel disease (IBD) on family members. Rev J Clin Nurs. 2023;32(9\u201310):2228\u201338. https:\/\/doi.org\/10.1111\/jocn.16446.","journal-title":"Rev J Clin Nurs."},{"key":"523_CR12","doi-asserted-by":"publisher","unstructured":"Coward S, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), et al. Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis. Am J Gastroenterol. 2024;119(8):1563\u201370. https:\/\/doi.org\/10.14309\/ajg.0000000000002687.","DOI":"10.14309\/ajg.0000000000002687"},{"issue":"5","key":"523_CR13","doi-asserted-by":"publisher","first-page":"P458","DOI":"10.1016\/S2468-1253(23)00003-1","volume":"8","author":"J Burisch","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology. Lancet Gastroenterol Hepatol. 2023;8(5):P458-492. https:\/\/doi.org\/10.1016\/S2468-1253(23)00003-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"523_CR14","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","volume":"162","author":"J Pan\u00e9s","year":"2022","unstructured":"Pan\u00e9s J, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891\u2013910.","journal-title":"Gastroenterology"},{"issue":"6","key":"523_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.cgh.2016.10.039","volume":"15","author":"R Shivashankar","year":"2017","unstructured":"Shivashankar R, et al. Incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857\u201363.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"523_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","volume":"5","author":"J Burisch","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kup\u010dinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454\u201364.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"Suppl 1","key":"523_CR17","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1093\/jcag\/gwy055","volume":"2","author":"ME Kuenzig","year":"2019","unstructured":"Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S17\u201333. https:\/\/doi.org\/10.1093\/jcag\/gwy055.","journal-title":"J Can Assoc Gastroenterol."},{"issue":"Suppl 2","key":"523_CR18","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/jcag\/gwad008","volume":"6","author":"ME Kuenzig","year":"2023","unstructured":"Kuenzig ME, Coward S, Targownik LE, Murthy SK, Benchimol EI, Windsor JW, et al. The 2023 impact of inflammatory bowel disease in Canada: direct health system and medication costs. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S23\u201334. https:\/\/doi.org\/10.1093\/jcag\/gwad008.","journal-title":"J Can Assoc Gastroenterol."},{"key":"523_CR19","doi-asserted-by":"publisher","unstructured":"van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, COIN Study Group and the Dutch Initiative on Crohn and Colitis, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study. Gut. 2014;63(1):72\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2012-303376.","DOI":"10.1136\/gutjnl-2012-303376"},{"key":"523_CR20","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"C Lamb","year":"2019","unstructured":"Lamb C, Kennedy N, Raines T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106. https:\/\/doi.org\/10.1136\/gutjnl-2019-318484.","journal-title":"Gut"},{"key":"523_CR21","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","volume":"50","author":"CN Bernstein","year":"2016","unstructured":"Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016;50:803\u201318. https:\/\/doi.org\/10.1097\/MCG.0000000000000660.","journal-title":"J Clin Gastroenterol"},{"key":"523_CR22","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1053\/j.gastro.2009.12.035","volume":"138","author":"FA Farraye","year":"2010","unstructured":"Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746\u201374. https:\/\/doi.org\/10.1053\/j.gastro.2009.12.035.","journal-title":"Gastroenterology"},{"key":"523_CR23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/jcag\/gwz019","volume":"2","author":"R Panaccione","year":"2019","unstructured":"Panaccione R, Steinhart H, Bressler B, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn\u2019s disease. J Can Assoc Gastroenterol. 2019;2:e1\u201334. https:\/\/doi.org\/10.1093\/jcag\/gwz019.","journal-title":"J Can Assoc Gastroenterol."},{"issue":"5","key":"523_CR24","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"key":"523_CR25","doi-asserted-by":"publisher","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, GEMINI 1 Study Group, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1215734.","DOI":"10.1056\/NEJMoa1215734"},{"key":"523_CR26","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, for the GEMINI 2 Study Group, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1215739","DOI":"10.1056\/NEJMoa1215739"},{"issue":"8","key":"523_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","volume":"19","author":"A Parikh","year":"2013","unstructured":"Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"523_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2147\/CEOR.S135609","volume":"9","author":"MR Wilson","year":"2017","unstructured":"Wilson MR, Zouraq IA, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017;9:641\u201352. https:\/\/doi.org\/10.2147\/CEOR.S135609.","journal-title":"Clinicoecon Outcomes Res."},{"key":"523_CR29","doi-asserted-by":"publisher","first-page":"175628482094117","DOI":"10.1177\/1756284820941179","volume":"13","author":"P Petryszyn","year":"2020","unstructured":"Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Ther Adv Gastroenterol. 2020;13:1756284820941179. https:\/\/doi.org\/10.1177\/1756284820941179.","journal-title":"Ther Adv Gastroenterol"},{"issue":"4","key":"523_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s41669-022-00331-9","volume":"6","author":"E Fenu","year":"2022","unstructured":"Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, et al. Cost Effectiveness of subcutaneous vedolizumab for maintenance treatment of ulcerative colitis in Canada. Pharmacoecon Open. 2022;6(4):519\u201337. https:\/\/doi.org\/10.1007\/s41669-022-00331-9.","journal-title":"Pharmacoecon Open."},{"issue":"8","key":"523_CR31","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1007\/s12325-021-01806-7","volume":"38","author":"T Zhou","year":"2021","unstructured":"Zhou T, Sheng Y, Guan H. Cost-effectiveness of vedolizumab in the treatment of moderate-to-severe Crohn\u2019s disease in China. Adv Ther. 2021;38(8):4233\u201345. https:\/\/doi.org\/10.1007\/s12325-021-01806-7.","journal-title":"Adv Ther"},{"issue":"1","key":"523_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2016-000093","volume":"3","author":"L Yokomizo","year":"2016","unstructured":"Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3(1): e000093. https:\/\/doi.org\/10.1136\/bmjgast-2016-000093.","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"523_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40273-019-00841-1","volume":"38","author":"L Hernandez","year":"2020","unstructured":"Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, et al. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2020;38(1):69\u201384. https:\/\/doi.org\/10.1007\/s40273-019-00841-1.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"523_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/13696998.2021.1881323","volume":"24","author":"A Sardesai","year":"2021","unstructured":"Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, et al. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ. 2021;24(1):279\u201390. https:\/\/doi.org\/10.1080\/13696998.2021.1881323.","journal-title":"J Med Econ"},{"issue":"6","key":"523_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/ejhpharm-2018-001833","volume":"27","author":"C Trigo-Vicente","year":"2020","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, L\u00f3pez-Del VA. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm. 2020;27(6):355\u201360. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001833.","journal-title":"Eur J Hosp Pharm"},{"issue":"2","key":"523_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10198-017-0879-5","volume":"19","author":"MR Wilson","year":"2018","unstructured":"Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Meta-analysis. Eur J Health Econ. 2018;19(2):229\u201340. https:\/\/doi.org\/10.1007\/s10198-017-0879-5.","journal-title":"Eur J Health Econ"},{"issue":"3","key":"523_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/14737167.2018.1411193","volume":"18","author":"C Trigo-Vicente","year":"2018","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allu\u00e9 R, L\u00f3pez-Del VA. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):321\u20139. https:\/\/doi.org\/10.1080\/14737167.2018.1411193.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"523_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/14737167.2021.1880324","volume":"22","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Andr\u00e9s-Nogales F, Garc\u00eda-L\u00f3pez S, S\u00e1nchez-Guerrero A, Mench\u00e9n B, Peral C, et al. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):73\u201383. https:\/\/doi.org\/10.1080\/14737167.2021.1880324.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"523_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.18553\/jmcp.2021.27.11.1592","volume":"27","author":"BG Schultz","year":"2021","unstructured":"Schultz BG, Diakite I, Carter JA, Snedecor SJ, Turpin R. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis. J Manag Care Spec Pharm. 2021;27(11):1592\u2013600. https:\/\/doi.org\/10.18553\/jmcp.2021.27.11.1592.","journal-title":"J Manag Care Spec Pharm"},{"key":"523_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.704889","volume":"9","author":"T Zhou","year":"2021","unstructured":"Zhou T, Sheng Y, Guan H, Meng R, Wang Z. Cost-effectiveness analysis of vedolizumab compared with infliximab in anti-TNF-\u03b1-na\u00efve patients with moderate-to-severe ulcerative colitis in China. Front Public Health. 2021;9: 704889. https:\/\/doi.org\/10.3389\/fpubh.2021.704889.","journal-title":"Front Public Health"},{"issue":"11","key":"523_CR41","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/ibd\/izy114","volume":"24","author":"B Wu","year":"2018","unstructured":"Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2018;24(11):2291\u2013302. https:\/\/doi.org\/10.1093\/ibd\/izy114.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"523_CR42","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"A Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management. J Crohns Colitis. 2010;4(1):28\u201362.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"523_CR43","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infiximab in infammatory bowel disease. Gastroenterology. 2006;130(3):940\u201387.","journal-title":"Gastroenterology"},{"issue":"6","key":"523_CR44","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/ibd.21506","volume":"17","author":"B Pariente","year":"2011","unstructured":"Pariente B, Cosnes J, Danese S, et al. Development of the Crohn\u2019s disease digestive damage score, the Lemann score. Infamm Bowel Dis. 2011;17(6):1415\u201322.","journal-title":"Infamm Bowel Dis."},{"issue":"3","key":"523_CR45","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/apt.14430","volume":"47","author":"H Yu","year":"2018","unstructured":"Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for infammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364\u201370.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"523_CR46","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","volume":"15","author":"B Bressler","year":"2021","unstructured":"Bressler B, Yarur A, Silverberg MS, Bassel M, Bellaguarda E, Fourment C, et al. Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE Study. J Crohns Colitis. 2021;15(10):1694\u2013706. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab058.","journal-title":"J Crohns Colitis"},{"key":"523_CR47","unstructured":"Takeda Canada Inc. CADTH common drug review: clinical and economic review report for vedolizumab (Entyvio SC). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2021. p. 1\u201392. SR0647-000."},{"key":"523_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"6","key":"523_CR49","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17474124.2021.1880319","volume":"15","author":"V Jairath","year":"2021","unstructured":"Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, et al. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(6):711\u201322.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"523_CR50","unstructured":"CADTH Common Drug Review: Pharmacoeconomic Review Report. Entyvio (vedolizumab). https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0487_Entyvio_PE_Report.pdf. Accessed 31 July 2024."},{"key":"523_CR51","unstructured":"Ontario Ministry of Health Schedule of Benefits for Laboratory Services [cited 22 Oct 2019]. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/"},{"key":"523_CR52","unstructured":"Ontario Case Costing Initiative (OCCI) Costing Analysis Tool [cited 23 Sep 2019]. https:\/\/stage.hsim.health.gov.on.ca\/hdbportal\/"},{"key":"523_CR53","unstructured":"Statistics Canada. Table 18-10-0004-01 Consumer Price Index, monthly, not seasonally adjusted. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000401"},{"issue":"Suppl. 1","key":"523_CR54","first-page":"A153","volume":"57","author":"A Woehl","year":"2008","unstructured":"Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis (402). Gut. 2008;57(Suppl. 1):A153.","journal-title":"Gut"},{"issue":"11","key":"523_CR55","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"key":"523_CR56","unstructured":"NICE Single Technology Appraisal. Vedolizumab for the treatment of adults with moderate to severe active ulcerative colitis. Single Technology Appraisal 2014."},{"issue":"11","key":"523_CR57","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2165\/00019053-200119110-00003","volume":"19","author":"RE Brown","year":"2001","unstructured":"Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19(11):1091\u2013102.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"523_CR58","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak. 2006;26(4):410\u201320.","journal-title":"Med Decis Mak"},{"key":"523_CR59","unstructured":"CADTH Guidelines for the Economic Evaluation of Health Technologies: Canada. https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-0"},{"key":"523_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376: e067975. https:\/\/doi.org\/10.1136\/bmj-2021-067975.","journal-title":"BMJ"},{"issue":"2","key":"523_CR61","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/2050640617708952","volume":"6","author":"P Baji","year":"2018","unstructured":"Baji P, Gul\u00e1csi L, Brodszky V, V\u00e9gh Z, Danese S, Irving PM, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn\u2019s disease across Europe. United Eur Gastroenterol J. 2018;6(2):310\u201321. https:\/\/doi.org\/10.1177\/2050640617708952.","journal-title":"United Eur Gastroenterol J."},{"issue":"7","key":"523_CR62","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40273-018-0653-2","volume":"36","author":"P Holko","year":"2018","unstructured":"Holko P, Kawalec P, Pilc A. Cost-effectiveness analysis of Crohn\u2019s disease treatment with vedolizumab and ustekinumab after failure of tumor necrosis factor-\u03b1 antagonist. Pharmacoeconomics. 2018;36(7):853\u201365. https:\/\/doi.org\/10.1007\/s40273-018-0653-2.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"523_CR63","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14737167.2017.1322509","volume":"17","author":"F Rencz","year":"2017","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Gecse KB, Dignass A, Halfvarson J, et al. Cost-utility of biological treatment sequences for luminal Crohn\u2019s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017;17(6):597\u2013606. https:\/\/doi.org\/10.1080\/14737167.2017.1322509.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00523-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:04:23Z","timestamp":1736427863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00523-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00523-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"22 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Takeda Pharmaceuticals International AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Aren Fischer is a former employee of Takeda Canada Inc. and is now an employee of Alexion Pharmaceuticals. Stephen Mac and Erica Stivelman Freiman are employees of Takeda Canada Inc. John K. Marshall has received honoraria for speaking and\/or consulting from AbbVie, Allergan, Amgen, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, Lilly, Lupin, Merck, Novartis, Paladin, Pfizer, Pharmascience, Procter & Gamble, Roche, Shire, Takeda, and Teva. Juan M. Ramos-Goni and Kim Rand are employees of Maths in Health, which received funding from Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participant data supporting the results reported in this article will be made available within 3 months from initial request, to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The model is proprietary and cannot be shared or published. If additional sensitivity analyses or scenarios are desired, please contact the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation and data collection and analysis were performed by Aren Fischer, Stephen Mac, Erica Stivelman Freiman, Kim Rand and Juan M. Ramos-Go\u00f1i. The first draft of the manuscript was written by Pedro Serrano and Anabel Estevez-Carillo as per content input from authors, and all authors commented on further versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Medical writing support was provided by Pedro Serrano and Anabel Estevez-Carillo of Maths in Health and was funded by Takeda.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical writing"}}]}}